Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The development of autoimmune features in aging mice is closely associated with alterations of the peripheral CD4⁺ T-cell compartment.

Nusser A, Nuber N, Wirz OF, Rolink H, Andersson J, Rolink A.

Eur J Immunol. 2014 Oct;44(10):2893-902. doi: 10.1002/eji.201344408. Epub 2014 Aug 25.

2.

In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.

Tsapogas P, Swee LK, Nusser A, Nuber N, Kreuzaler M, Capoferri G, Rolink H, Ceredig R, Rolink A.

Haematologica. 2014 Apr;99(4):638-46. doi: 10.3324/haematol.2013.089482. Epub 2014 Jan 24.

3.

NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.

von Boehmer L, Mattle M, Bode P, Landshammer A, Schäfer C, Nuber N, Ritter G, Old L, Moch H, Schäfer N, Jäger E, Knuth A, van den Broek M.

Cancer Immun. 2013 Jul 15;13:12. Print 2013.

4.

MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.

Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanackovic D, Knuth A, van den Broek M.

Leukemia. 2013 Aug;27(8):1767-9. doi: 10.1038/leu.2013.31. Epub 2013 Feb 1. No abstract available.

PMID:
23429573
5.

A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.

Gupta A, Nuber N, Esslinger C, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, van den Broek M.

Cancer Immun. 2013;13:3. Epub 2013 Jan 15.

6.

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.

Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den Broek M, Moch H.

PLoS One. 2011;6(6):e21418. doi: 10.1371/journal.pone.0021418. Epub 2011 Jun 27.

7.

Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.

Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15187-92. doi: 10.1073/pnas.1002155107. Epub 2010 Aug 9.

8.

Yeast-based identification of prostate tumor antigens provides an effective vaccine platform.

Jung V, Fischer E, Imig J, Kleber S, Nuber N, Reinshagen F, Kamradt J, Grobholz R, Knuth A, Renner C, Wadle A.

Anticancer Res. 2010 Mar;30(3):895-902.

PMID:
20393012
9.

Rational development of high-affinity T-cell receptor-like antibodies.

Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Nuber N, Stenner-Liewen F, Bauer S, McMichael A, Knuth A, Abken H, Hombach AA, Cerundolo V, Jones EY, Renner C.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5784-8. doi: 10.1073/pnas.0901425106. Epub 2009 Mar 23. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10872. Nuber, Natko [added].

10.

Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.

Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A.

Cancer Immunol Immunother. 2009 Mar;58(3):325-38. doi: 10.1007/s00262-008-0556-8. Epub 2008 Jul 29.

11.

MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma.

Curioni-Fontecedro A, Knights AJ, Tinguely M, Nuber N, Schneider C, Thomson CW, von Boehmer L, Bossart W, Pahlich S, Gehring H, Moch H, Renner C, Knuth A, Zippelius A.

Leukemia. 2008 Aug;22(8):1646-8. doi: 10.1038/leu.2008.43. Epub 2008 Mar 6. No abstract available.

PMID:
18323799
12.

Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.

Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Lévy F, Knuth A, Jäger D, Zippelius A.

J Immunol. 2006 Dec 1;177(11):8212-8.

Supplemental Content

Support Center